Method for stabilizing protein contained in sample, solution for stabilizing protein contained in sample
By adding aryl boric acid and sugar to the sample to form a stable solution, the problem of modification or decomposition of proteins such as hemoglobin during transportation is solved, and accurate detection in immunologic assays is achieved, which improves the reliability of the detection.
Patent Information
- Application Number
- CN201980016412.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-03-02
- Filing Date
- 2019-02-28
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2039-02-28
AI Technical Summary
Feces, urine, saliva, etc. are derived from proteins such as hemoglobin in living samples during transportation due to temperature changes and decomposition of bacteria or enzymes, resulting in antibodies being unable to be recognized and accurately detected through immunologic assays. The existing stable methods have not been able to Prevent it from modification or decomposition.
Add aryl boric acid and sugar to the sample to form a stable solution, improve the complex of hemoglobin and bound globin, prevent the modification, decomposition or modification of the protein, and ensure its stability in immunologic assays.
It significantly improves the stability of proteins such as hemoglobin in living samples, ensures accurate detection through immunologic assays, and enhances the reliability of the detection.
Smart Images

Figure BDA0002659218930000121 
Figure BDA0002659218930000131 
Figure BDA0002659218930000132
Abstract
Description
Technical Field
[0001] The present invention relates to a method for stabilizing a protein contained in a sample derived from a living organism, a stabilizing solution for stabilizing a protein contained in a sample derived from a living organism, and a method and a kit for detecting a protein contained in a sample derived from a living organism. Background Art
[0002] Detection of proteins contained in samples such as stool, urine, and saliva is used to diagnose a variety of diseases. For example, a fecal occult blood test that detects blood in a stool sample can provide important information for the diagnosis of digestive organ diseases, mainly colorectal cancer. As for methods for detecting blood proteins such as hemoglobin, haptoglobin, and hemoglobin-haptoglobin complexes contained in samples such as stool, there are known immunological assays that use antibodies against these proteins for detection.
[0003] Usually, the sample for occult blood test is collected by the test subject himself / herself into a storage container filled with a storage solution, and then transported to a testing institution such as a hospital. In most cases, it takes several days to transport the storage solution (specimen) containing the sample, and temperature management during transportation is generally difficult, so it is often placed under temperature conditions that are not conducive to storage. If the blood protein and other proteins contained in the sample are modified due to the temperature conditions during transportation, or are decomposed or modified by bacteria or enzymes in the sample, and the epitope or its surrounding structure changes, the antibody will not be able to recognize the protein contained in these feces, and accurate measurement cannot be performed by immunological assays. In particular, hemoglobin is unstable in solution and is particularly prone to modification or decomposition under high temperature conditions.
[0004] As a technology for stabilizing hemoglobin in a preservation solution, various methods have been proposed, for example: a method of adding antibacterial agents such as thimerosal and chlorhexidine (for example, Patent Document 1); a method of adding a protease inhibitor (for example, Patent Document 2); a method of adding a glycosidase-type lyase (for example, Patent Document 3); a method of adding an enzymatic degradation product of hemoglobin (for example, Patent Document 4); a method of adding an organic acid such as malic acid (for example, Patent Document 5); a method of adding an aminocarboxylic acid (for example, Patent Document 6); and a method of adding a halogenated alkanesulfonic acid (for example, Patent Document 7), etc.
[0005] Furthermore, in order to stabilize hemoglobin, there is also a known method of adding haptoglobin (e.g., Patent Document 8). It is known that haptoglobin exists in the blood of many animals and can quickly bind to hemoglobin to form a stable hemoglobin-haptoglobin complex (Hb-Hp complex). By pre-adding haptoglobin to a storage solution for storing samples such as feces, when adding samples such as feces, hemoglobin contained in the sample derived from the living body can be converted into a stable hemoglobin-haptoglobin complex.
[0006] However, since hemoglobin is very unstable, even these hemoglobin stabilization methods have not been able to fully prevent its modification or decomposition. Therefore, although there are known methods for detecting fecal occult blood, which have a better stability than hemoglobin, transferrin (e.g., Patent Document 9), the transferrin in the blood is only about 1 / 60 of hemoglobin, so there is a problem of low sensitivity.
[0007] Prior art literature
[0008] Patent Literature
[0009] Patent Document 1: Japanese Patent Application Laid-Open No. 63-271160
[0010] Patent Document 2: Japanese Patent Application Laid-Open No. 3-279859
[0011] Patent Document 3: Japanese Patent Application Laid-Open No. 63-246667
[0012] Patent Document 4: Japanese Patent Application Laid-Open No. 11-218533
[0013] Patent Document 5: Japanese Patent Application Publication No. 2003-14768
[0014] Patent Document 6: Japanese Patent Application Publication No. 2009-097956
[0015] Patent Document 7: Japanese Patent Application Publication No. 2016-191580
[0016] Patent Document 8: Japanese Patent Application Laid-Open No. 10-132824
[0017] Patent Document 9: Japanese Patent Application Laid-Open No. 63-246668 Summary of the invention
[0018] Problem that the invention aims to solve
[0019] Since samples derived from living organisms such as feces, urine, and saliva, especially feces, often contain bacteria or enzymes that cause the degradation or modification of proteins such as hemoglobin, even a protein with high stability such as the hemoglobin-haptoglobin complex may be degraded or modified.
[0020] Therefore, an object of the present invention is to provide a method for improving stability even under adverse temperature conditions in which proteins contained in a sample derived from a living body are easily decomposed or denatured.
[0021] Means of solving the problem
[0022] (1) A method for stabilizing a protein contained in a sample derived from a living organism, comprising the steps of allowing the protein contained in the sample derived from a living organism to coexist with an arylboronic acid,
[0023] The protein contained in the living body-derived sample is at least one selected from the group consisting of hemoglobin, haptoglobin, and a hemoglobin-haptoglobin complex.
[0024] (2) The method according to (1), wherein the aryl boronic acid is at least one selected from the group consisting of phenylboronic acid and derivatives thereof.
[0025] (3) The method according to (1) (2), wherein the aryl boronic acid is at least one selected from the group consisting of phenylboronic acid, hydroxyphenylboronic acid, carboxyphenylboronic acid, aminophenylboronic acid, and salts of these boronic acids.
[0026] (4) The method according to any one of (1) to (3), wherein the step is a step of dispersing the protein contained in the sample derived from a living body in a solution containing the arylboronic acid,
[0027] The concentration of the arylboronic acid in the solution is greater than 0.1 mmol / L.
[0028] (5) The method according to any one of (1) to (4), wherein the step is a step of allowing the protein contained in the sample derived from the living body to coexist with the arylboronic acid and the sugar.
[0029] (6) The method according to (5), wherein the sugar is at least one selected from the group consisting of sugar alcohols, monosaccharides and disaccharides.
[0030] (7) The method according to (5) to (6), wherein the sugar is at least one selected from the group consisting of sorbitol, glucose, mannitol, fructose, xylitol, erythritol, sucrose, trehalose, lactose, and maltose.
[0031] (8) The method according to any one of (5) to (7), wherein the step is a step of dispersing the protein contained in the sample derived from a living body in a solution containing the arylboronic acid and the sugar,
[0032] The concentration of the sugar in the solution is above 5 mmol / L.
[0033] (9) The method according to any one of (1) to (8), wherein the living body-derived sample includes at least hemoglobin,
[0034] The method comprises the step of contacting the hemoglobin with haptoglobin to form a complex of the hemoglobin and the haptoglobin.
[0035] (10) According to the method described in (1) to (9), the sample derived from a living body is feces, saliva, or urine.
[0036] (11) A stabilizing solution for stabilizing a protein contained in a sample derived from a living body,
[0037] It contains arylboronic acid,
[0038] The protein contained in the living body-derived sample is at least one selected from the group consisting of hemoglobin, haptoglobin, and a hemoglobin-haptoglobin complex.
[0039] (12) The stable solution according to (11), wherein the aryl boronic acid is at least one selected from the group consisting of phenylboronic acid and derivatives thereof.
[0040] (13) The stable solution according to (11) to (12), wherein the aryl boronic acid is at least one selected from the group consisting of phenylboronic acid, hydroxyphenylboronic acid, carboxyphenylboronic acid, aminophenylboronic acid, and salts of these boronic acids.
[0041] (14) The stable solution according to any one of (11) to (13), which contains sugar.
[0042] (15) According to the stable solution described in (14), the sugar is at least one selected from the group consisting of sorbitol, glucose, mannitol, fructose, xylitol, erythritol, sucrose, trehalose, lactose, and maltose.
[0043] (16) The stable solution according to any one of (11) to (15), which contains haptoglobin.
[0044] (17) The stable solution according to any one of (11) to (16), wherein the sample is feces, saliva, or urine.
[0045] (18) The stabilizing solution according to any one of (11) to (17), which is a solution for preserving the sample derived from a living organism.
[0046] (19) A method for detecting a protein in a sample derived from a living body, comprising:
[0047] A step of adding the sample derived from a living body to the stabilizing solution described in (11) to (18) to obtain a test specimen containing the sample; and
[0048] The step of detecting the protein in the sample by an immunological assay method,
[0049] The protein in the living body-derived sample is at least one selected from the group consisting of hemoglobin, haptoglobin, and a hemoglobin-haptoglobin complex.
[0050] (20) The method according to (19), wherein the living body-derived sample includes at least hemoglobin, and the hemoglobin in the sample forms a complex with haptoglobin.
[0051] (21) According to the method described in (20), the stable solution is the stable solution described in (16).
[0052] (22) A kit for detecting a protein contained in a sample derived from a living body, comprising:
[0053] The stable solution described in (11) to (18), and
[0054] a reagent containing an antibody that recognizes the protein,
[0055] The protein is at least one selected from the group consisting of hemoglobin, haptoglobin, and a hemoglobin-haptoglobin complex.
[0056] Effects of the Invention
[0057] According to the present invention, it is possible to stabilize proteins such as blood proteins contained in a sample derived from a living body. In other words, according to the present invention, it is possible to prevent the denaturation, decomposition or modification of proteins such as blood proteins contained in a sample derived from a living body. Therefore, according to the present invention, it is possible to accurately measure proteins contained in a sample derived from a living body by an immunological measurement method. DETAILED DESCRIPTION
[0058] Hereinafter, preferred embodiments of the present invention will be described.
[0059] (Method for stabilizing protein contained in a sample derived from a living organism, protein stabilizing solution)
[0060] One embodiment of the present invention provides a method for stabilizing a protein contained in a sample derived from a living body, comprising the step of allowing the protein contained in the sample derived from a living body to coexist with an arylboronic acid. In this embodiment, the protein contained in the sample derived from a living body may be at least one selected from the group consisting of hemoglobin, haptoglobin, and a hemoglobin-haptoglobin complex.
[0061] By allowing the protein contained in the sample derived from a living organism to coexist with the arylboronic acid, the stability of the protein contained in the sample derived from a living organism can be improved. The sample derived from a living organism containing the protein may be feces, saliva, or urine, or may be feces.
[0062] The method of making the protein contained in the sample derived from a living organism coexist with the arylboronic acid is not particularly limited, and an example thereof includes a method of dispersing the protein contained in the sample derived from a living organism in a solution containing the arylboronic acid. Here, "dispersing" includes dissolving and suspending.
[0063] Examples of the solution containing the arylboronic acid include a storage solution for storing a sample derived from a living organism, a dilution solution for further diluting a specimen obtained by dispersing the sample in the storage solution, and a reaction solution in a kit for detecting a protein in a sample. In particular, according to the present embodiment, since the stability of a protein contained in a sample derived from a living organism can be significantly improved, the storage solution for the sample can be preferably used.
[0064] The aryl boronic acid can be appropriately selected from known aryl boronic acids. The aryl boronic acid can be at least one selected from the group consisting of phenylboronic acid and its derivatives, or at least one selected from the group consisting of phenylboronic acid, hydroxyphenylboronic acid, carboxyphenylboronic acid, aminophenylboronic acid and salts of these boronic acids, or at least one selected from the group consisting of phenylboronic acid, 3-hydroxyphenylboronic acid, 2-carboxyphenylboronic acid, 3-carboxyphenylboronic acid, 4-carboxyphenylboronic acid, 3-aminophenylboronic acid and salts of these boronic acids, and in particular, at least one selected from the group consisting of phenylboronic acid, 3-hydroxyphenylboronic acid, 3-carboxyphenylboronic acid, 3-aminophenylboronic acid and salts of these boronic acids.
[0065] The lower limit of the arylboronic acid concentration in the solution is preferably 0.1 mmol / L or more, 0.2 mmol / L or more, or 0.5 mmol / L or more. When the arylboronic acid concentration is greater than the lower limit, the stabilizing effect on proteins contained in a sample derived from a living body is more excellent.
[0066] In addition, the upper limit of the concentration of the aryl boronic acid in the above solution is preferably 100 mmol / L or less, 50 mmol / L or less, or 30 mmol / L or less. If the concentration of the aryl boronic acid is too high, the apparent recovery rate is sometimes reduced when the protein contained in the sample derived from the living body is measured by the immunoassay. It is considered that this is not a decrease in the stabilizing effect of the protein contained in the sample derived from the living body, but that the high concentration of aryl boronic acid has an adverse effect on the immunoassay. However, if the concentration of the aryl boronic acid is below the above upper limit, the adverse effect on the immunoassay can be suppressed, and the measurement can be performed more accurately.
[0067] However, even when a high concentration of arylboronic acid is contained in the solution, when it coexists with a high concentration of sugar described later, the adverse effect of the high concentration of arylboronic acid on the immunological assay method can be suppressed by forming a complex between the arylboronic acid and the sugar. Therefore, even when the concentration of the arylboronic acid is about 50 mmol / L or even about 100 mmol / L in the presence of a high concentration of sugar, accurate measurement by the immunological assay can be ensured.
[0068] In a more specific aspect of this embodiment, the aryl boronic acid can be included in a solution (stabilizing solution) for stabilizing proteins contained in a sample derived from a living body. For example, when the stabilizing solution does not contain haptoglobin described later, the lower limit of the concentration of the aryl boronic acid in the stabilizing solution can be 0.1 mmol / L or more, 0.2 mmol / L or more, or 0.5 mmol / L or more. In addition, the upper limit of the concentration of the aryl boronic acid in the stabilizing solution can be 20 mmol / L or less, 10 mmol / L or less, or 5 mmol / L or less.
[0069] The above step may be a step of allowing the protein contained in the sample derived from a living organism to coexist with the above aryl boronic acid and further with sugar. By allowing the sugar to coexist in addition to the aryl boronic acid, the stability of the protein contained in the sample derived from a living organism can be further improved. For example, a method of allowing the protein contained in the sample derived from a living organism to coexist with sugar can include further containing sugar in the solution containing the above aryl boronic acid.
[0070] The sugar can be appropriately selected from known sugars, and examples thereof include sugar alcohols such as sorbitol, mannitol, xylitol, and erythritol; monosaccharides such as glucose, fructose, mannose, and galactose; disaccharides such as sucrose, trehalose, lactose, and maltose; and oligosaccharides.
[0071] The sugar may be at least one selected from the group consisting of sugar alcohols, monosaccharides and disaccharides, may be at least one selected from the group consisting of sorbitol, glucose, mannitol, fructose, xylitol, erythritol, sucrose, trehalose, lactose, and maltose, or may be at least one selected from the group consisting of sorbitol, mannitol, fructose, and sucrose.
[0072] However, since glucose and fructose etc. form sugars (reducing sugars) of aldehyde or ketone groups in solution, they react with proteins contained in samples derived from living organisms or albumin added to the solution as stabilizers of these proteins etc. (Maillard reaction), proteins are modified to generate brown substances (protein melanin), so sugars that do not react with proteins are preferably used. If the epitope of proteins contained in samples derived from living organisms or their vicinity is modified by reducing sugars and the structure changes, sometimes the proteins contained in the samples derived from living organisms cannot be identified by antibodies, and accurate determination cannot be performed by immunological assays. Therefore, a more specific aspect of the present embodiment is more preferably to use non-reducing sugars that do not react with proteins. Non-reducing sugars can be at least one selected from the group consisting of sorbitol, mannitol, xylitol, erythritol, trehalose, sucrose and lactose, and can be at least one selected from the group consisting of sorbitol, mannitol and sucrose.
[0073] The lower limit of the sugar concentration is preferably 5 mmol / L or more, 10 mmol / L or more, or 25 mmol / L or more. When the sugar concentration is above the lower limit, it acts synergistically with the arylboronic acid to achieve a more excellent stabilizing effect on proteins contained in a sample derived from a living body.
[0074] The upper limit of the sugar concentration may be 1000 mmol / L or less, 500 mmol / L or less, or 100 mmol / L or less for sugar alcohols and monosaccharides, and 500 mmol / L or less, 250 mmol / L or less, or 100 mmol / L or less for disaccharides. If the sugar concentration is below the upper limit, the viscosity of the stable solution will not be too high, so it is unlikely to affect the measurement.
[0075] The stabilizing solution for preserving proteins contained in samples derived from living organisms can be any buffer solution whose pH is maintained at 5-10, preferably 6-8. It can be a buffer solution including Good's buffer such as 2-morpholineethanesulfonic acid (MES), hydroxyethylpiperazine-2-ethanesulfonic acid (HEPES), piperazine bis(2-ethanesulfonic acid) (PIPES), or a phosphate buffer, Tris buffer or glycine buffer.
[0076] The stabilizing solution may further contain additives such as antimicrobial agents, pH regulators, salts for adjusting ionic strength, surfactants, aggregation promoters, and known stabilizers used for preserving proteins. Antimicrobial agents include sodium azide, antibiotics, and lysozyme. Additives include known substances known to have the effect of stabilizing proteins, such as amino acids such as histidine and lysine, albumin, protease inhibitors, and chelating agents such as ethylenediaminetetraacetic acid (EDTA).
[0077] According to the above-mentioned stabilization method or stabilization solution, the stability of the protein contained in the sample derived from the living body can be improved by the action of the aryl boronic acid or by the synergistic action of the aryl boronic acid and sugar. In other words, according to the above-mentioned stabilization method or stabilization solution, the modification, decomposition or modification of the protein contained in the sample derived from the living body can be prevented, and the structure of the epitope of the protein contained in the sample derived from the living body and its surrounding parts can be maintained. Therefore, when the protein contained in the sample derived from the living body is detected by an immunological assay method, it can be expected that the accuracy of the detection can be improved.
[0078] A more specific aspect of this embodiment may include a step of forming a hemoglobin-haptoglobin complex by contacting a living body sample containing at least hemoglobin with haptoglobin. In this case, the living body sample containing hemoglobin may be feces, saliva, or urine, or feces. In feces, there are particularly many bacteria or enzymes that cause the decomposition or modification of hemoglobin, so the method of this embodiment is particularly useful.
[0079] The sample derived from a living body containing hemoglobin can be contacted with haptoglobin in any manner, but it is preferred that the sample derived from a living body containing hemoglobin is added to the storage solution containing haptoglobin. The hemoglobin contained in the sample derived from the living body reacts rapidly with the haptoglobin in the storage solution to form a hemoglobin-haptoglobin complex. Then, by directly storing the storage solution to which the sample derived from the living body is added, the hemoglobin-haptoglobin complex can be stably stored. In addition, during the formation of the complex between hemoglobin and haptoglobin, hemoglobin dissociates from a 4-mer (α2β2) in which the α chain and the β chain are associated in pairs into two 2-mers (αβ), and this phenomenon is not equivalent to "decomposition" or "modification" in this specification.
[0080] The stabilizing solution provided by the present embodiment for stabilizing proteins contained in a sample derived from a living body containing hemoglobin is preferably a solution in which haptoglobin is further added to the above-mentioned stabilizing solution containing an arylboronic acid or an arylboronic acid and a sugar. The concentration of haptoglobin in the stabilizing solution depends on the amount of the sample derived from the living body, for example, 0.05 units / L-50 units / L, 0.1 units / L-10 units / L, or 0.2 units / L-2 units / L. Here, 1 unit represents the amount of haptoglobin bonded to 1 mg of hemoglobin. The above-mentioned range of haptoglobin concentration is a concentration sufficient to convert all hemoglobin in a sample derived from a living body into a hemoglobin-haptoglobin complex.
[0081] Here, when the stabilizing solution contains haptoglobin described later, the lower limit of the concentration of the arylboronic acid in the stabilizing solution may be 0.1 mmol / L or more, 0.2 mmol / L or more, 0.5 mmol / L or more, 1 mmol / L or more, or 5 mmol / L or more. When the concentration of the arylboronic acid is equal to or higher than the lower limit, the stabilizing effect of the arylboronic acid on hemoglobin contained in the sample derived from the living body is combined with the stabilizing effect of haptoglobin on the hemoglobin, and the effect is more significant.
[0082] In addition, the upper limit of the concentration of the aryl boronic acid in the stabilizing solution may be 100 mmol / L or less, 50 mmol / L or less, or 30 mmol / L or less. If the concentration of the aryl boronic acid is below the upper limit, adverse effects on the immunoassay can be suppressed, and more accurate measurements can be performed.
[0083] According to the stabilization method or stabilization solution provided in the above aspect, hemoglobin contained in a sample derived from a living body can be stably preserved in the form of a hemoglobin-haptoglobin complex. In other words, according to the above stabilization method or stabilization solution, the modification, decomposition or modification of hemoglobin contained in a sample derived from a living body can be prevented, and the structure of the epitope of hemoglobin and its surrounding parts can be maintained. Therefore, when the hemoglobin contained in a sample derived from a living body is measured by an immunological measurement method, it can be expected that the accuracy of the detection can be improved.
[0084] (Method and kit for detecting proteins contained in samples derived from living organisms)
[0085] A method for detecting a protein contained in a sample derived from a living organism provided by one embodiment of the present invention comprises: adding the sample derived from a living organism to the above-mentioned stabilizing solution for stabilizing the protein to obtain a sample including the sample derived from a living organism; and detecting the protein in the sample by an immunological assay method.
[0086] In addition, another embodiment of the present invention provides a kit for detecting a protein contained in a sample derived from a living organism, comprising: the above-mentioned stabilizing solution, and a reagent containing an antibody that recognizes the protein contained in the sample derived from a living organism.
[0087] In the above detection method or detection kit, the protein contained in the sample derived from a living body may be at least one selected from the group consisting of hemoglobin, haptoglobin, and a hemoglobin-haptoglobin complex.
[0088] Examples of the stabilizing solution used in this embodiment include a storage solution for storing a sample derived from a living body, a dilution solution for further diluting a sample dispersed in a storage solution, and a reaction solution in a kit for detecting proteins in a sample. The reaction solution in the kit includes, in addition to a solution containing an antibody in an immunological assay described later, a solution for mixing with a sample to adjust the assay environment.
[0089] The immunological measurement method is a method using antibodies against proteins contained in a sample derived from a living body, and a known immunological measurement method can be used. Examples of the immunological measurement method include immunoagglutination methods such as latex agglutination and gold colloid agglutination, immunochromatography, or ELISA.
[0090] The antibody against the protein contained in the living organism sample is not limited and may be a polyclonal antibody, a monoclonal antibody, or a fragment of an antibody against the protein contained in the living organism sample that can recognize the protein contained in the living organism sample.
[0091] The antibody against a protein contained in a sample derived from a living body may be any antibody capable of recognizing the protein to be measured, and may be an anti-hemoglobin antibody, an anti-haptoglobin antibody, or an anti-hemoglobin-haptoglobin complex antibody. These antibodies can be produced by conventional methods.
[0092] As an example of detecting proteins contained in a sample derived from a living body, such as hemoglobin, it can be carried out as follows. First, a sample is added to a container containing a storage solution as a test sample. The sample can be stored in the container for any period of time, or the storage solution containing the sample can be filtered as a test sample. Next, the hemoglobin in the sample is detected by an immunological assay method, such as a latex agglutination method. More specifically, a reagent containing latex particles with anti-hemoglobin antibodies loaded on the surface is added to the sample. Before adding the reagent containing the latex particles, the sample can be diluted with a diluent, or a reaction solution can be added. In this aspect, the above-mentioned stable solution containing an aryl boronic acid can be any one of a storage solution, a diluent, and a reaction solution. It is particularly preferred when the storage solution is the above-mentioned stable solution, in which case the diluent and / or the reaction solution may contain an aryl boronic acid or may not contain an aryl boronic acid.
[0093] In a sample derived from a living body, hemoglobin may form a complex with haptoglobin in the sample or may exist as free hemoglobin. Therefore, it is preferred that the anti-hemoglobin antibody used for the detection of hemoglobin can recognize an epitope of free hemoglobin and an epitope of hemoglobin in a hemoglobin-haptoglobin complex and does not cause a cross reaction with haptoglobin.
[0094] When hemoglobin is present in the sample, the anti-hemoglobin antibody recognizes hemoglobin, and the antibody-loaded latex particles aggregate. The change in turbidity caused by aggregation is measured, and the hemoglobin concentration in the sample is obtained by using a calibration curve prepared using a calibrant containing hemoglobin of known concentration. In addition, the hemoglobin concentration in the sample can also be obtained by using a calibration curve prepared based on the hemoglobin concentration of the calibrant.
[0095] In the case where the above-mentioned stabilizing solution contains haptoglobin, the detection of hemoglobin can be carried out, for example, as follows. First, a sample is added to a container containing a storage solution as a test specimen. The sample can be stored in the container for any period of time, or the storage solution containing the sample can be filtered as a test specimen. Next, the hemoglobin in the sample is detected by an immunological assay method, such as a latex agglutination method. More specifically, a reagent containing latex particles with anti-hemoglobin antibodies loaded on the surface is added to the sample. Before adding the reagent containing the latex particles, the sample can be diluted with a diluent, or a reaction solution can be added.
[0096] In the present aspect, the stable solution containing the arylboronic acid and haptoglobin may be any of a storage solution, a dilution solution, and a reaction solution.
[0097] It is particularly preferred if the storage solution is a stable solution containing an aryl boronic acid and haptoglobin. In this case, the diluent and / or reaction solution may or may not contain haptoglobin and further may or may not contain an aryl boronic acid.
[0098] In this aspect, when hemoglobin is present in the sample, the hemoglobin reacts with haptoglobin contained in the stabilizing solution to form a hemoglobin-haptoglobin complex. It is not necessary for all hemoglobin in the sample to form a complex, and hemoglobin that has not formed a complex with haptoglobin may exist in the stabilizing solution (sample) containing the sample, but it is preferred that all hemoglobin in the sample forms a complex with haptoglobin.
[0099] Preferably, the anti-hemoglobin antibody is capable of recognizing an epitope of hemoglobin in the hemoglobin-haptoglobin complex and does not cause cross-reaction with haptoglobin.
[0100] When hemoglobin is present in the sample, the anti-hemoglobin antibody recognizes hemoglobin (including hemoglobin that has formed a complex with haptoglobin), and the latex particles loaded with the antibody aggregate. The change in turbidity caused by aggregation is measured, and the hemoglobin concentration in the sample is obtained by using a calibration curve prepared using a calibrant of a hemoglobin-haptoglobin complex containing a known concentration of hemoglobin. In addition, the concentration of the hemoglobin-haptoglobin complex in the sample can also be obtained by using a calibration curve prepared based on the concentration of the hemoglobin-haptoglobin complex of the calibrant.
[0101] The above described embodiments are for facilitating the understanding of the present invention and are not intended to limit the present invention. Therefore, each element disclosed in the above embodiments is intended to include all design changes and equivalents belonging to the technical scope of the present invention.
[0102] Example
[0103] Example 1
[0104] A storage solution was prepared to which 40 mmol / L HEPES (pH 6.8), 0.1% BSA, 0.1% NaN3, 1 unit / L haptoglobin, and 0-100 mmol / L phenylboronic acid were added. A stool sample to which hemoglobin was added was added to the storage solution to obtain a stool concentration of 0.5%, and the sample was stored at 37°C for 0, 7, 14, and 21 days. In addition, hemoglobin was added to the stool sample in such an amount that the hemoglobin concentration in the sample became approximately 300 μg / L. Instead of the stool sample to which hemoglobin was added, hemoglobin was added to the storage solution, and a sample not containing a stool sample was similarly stored to obtain a hemoglobin concentration of 300 μg / L in the sample. The hemoglobin (Hb) concentration (μg / L) in the stored sample was measured using the latex agglutination method.
[0105] The hemoglobin concentration was measured using "OC-Hemodia (registered trademark) autoⅢ'Eiken'" (manufactured by Japan Eiken Chemical Co., Ltd.) as a measuring reagent and "OC-sensor DIANA" (manufactured by Japan Eiken Chemical Co., Ltd.) as a measuring device. The measuring reagent includes latex particles loaded with anti-human hemoglobin rabbit polyclonal antibodies.
[0106] Based on the measured hemoglobin concentration, the recovery rate (%) relative to the hemoglobin concentration after the stool sample was added to the storage solution (i.e., the concentration 0 days after the stool sample was added) was calculated. The results are shown in Table 1. As can be seen from Table 1, in any sample of Feces 1, Feces 2 and Feces 3, the recovery rate of hemoglobin in the sample was improved by adding phenylboronic acid at a concentration of 0.5mmol / L or more. The recovery rate of hemoglobin increased with the increase of phenylboronic acid concentration, and the maximum phenylboronic acid concentration was 15mmol / L. When 50mmol / L or more was added, the apparent recovery rate decreased. In the sample without stool sample, no increase in the recovery rate due to the addition of phenylboronic acid was found. These results show that phenylboronic acid stabilizes hemoglobin in the sample containing stool. In addition, since the hemoglobin in the sample exists as a hemoglobin-binding globin complex bound to the binding globin contained in the storage solution, the above results mean that phenylboronic acid stabilizes the hemoglobin-binding globin complex.
[0107] Table 1
[0108]
[0109]
[0110] Example 2
[0111] Instead of phenylboronic acid in the storage solution of Example 1, a storage solution to which 15 mmol / L of 2-carboxyphenylboronic acid (2-CPBA), 3-carboxyphenylboronic acid (3-CPBA), 4-carboxyphenylboronic acid (4-CPBA), 3-hydroxyphenylboronic acid (3-HPBA) and 3-aminophenylboronic acid (3-APBA) were added was prepared, and the test was carried out in the same manner as in Example 1. As a comparative example, a storage solution without adding arylboronic acid was prepared, and the same test was carried out. The results are shown in Table 2. As can be seen from Table 2, even when other arylboronic acids were used, the recovery rate of hemoglobin in the sample was improved in any of the stool samples of Stool 1, Stool 2 and Stool 3, compared with the comparative example without adding arylboronic acid.
[0112] Table 2
[0113]
[0114] Example 3
[0115] The concentration of phenylboronic acid in the storage solution of Example 1 was fixed at 15 mmol / L, and a storage solution to which 50 mmol / L or 100 mmol / L of sugar (sorbitol, sucrose, trehalose, glucose, fructose, or mannitol) was further added, or a storage solution without sugar was prepared, and the test was carried out in the same manner as in Example 1. As a comparative example, a storage solution without adding phenylboronic acid and sugar was prepared, and the same test was carried out. The results are shown in Table 3. As can be seen from Table 3, when sorbitol, mannitol, sucrose, or fructose was further added to phenylboronic acid, the recovery rate of hemoglobin in the sample was further improved in any of the stool samples of Stool 1, Stool 2, and Stool 3, and the recovery rate in sorbitol and mannitol was significantly improved. However, a stool sample (Stool 3) in which no recovery rate was found was observed in trehalose or glucose. These results show that the stability of hemoglobin in a sample containing feces can be further improved by further adding sugar to phenylboronic acid, but the effect varies depending on the type of sugar added. Among sorbitol, sucrose, trehalose, glucose, fructose, or mannitol, sorbitol and mannitol have the most significant effects, and sorbitol in particular did not cause any decrease in the recovery rate in the feces sample (feces 1).
[0116] Table 3
[0117]
[0118]
[0119] Example 4
[0120] A storage solution in which 100 mmol / L of sorbitol, sucrose, trehalose, glucose, fructose, or mannitol was added to the storage solution of Example 1 not containing phenylboronic acid was prepared, and the test was performed in the same manner as in Example 1. For comparison, the same test was performed without adding these sugars. The results are shown in Table 4. As can be seen from Table 4, even if sorbitol, sucrose, trehalose, glucose, or fructose is added to the storage solution not containing phenylboronic acid, the recovery rate of hemoglobin in the sample containing the stool sample does not increase. This result shows that sugars such as sorbitol, sucrose, trehalose, glucose, or fructose alone do not stabilize hemoglobin in the sample containing stool, indicating that phenylboronic acid and sugars need to coexist.
[0121] Table 4
[0122]
[0123]
[0124] Example 5
[0125] The phenylboronic acid of the storage solution of Example 1 was fixed at 15 mmol / L, and a storage solution to which 10-500 mmol / L of sorbitol or 10-250 mmol / L of sucrose was added, or a storage solution without sugar was prepared, and the test was carried out in the same manner as in Example 1. As a comparative example, a storage solution without phenylboronic acid and sugar was prepared, and the same test was carried out. The results are shown in Table 5. As can be seen from Table 5, in any sample of feces 1, feces 2, and feces 3, the recovery rate of hemoglobin in the sample containing feces increased with the increase in the added concentration of sorbitol or sucrose, and tended to be stable when 25 mmol / L or more was added.
[0126] Table 5
[0127]
[0128]
[0129] Example 6
[0130] Instead of phenylboronic acid in the storage solution of Example 1, a storage solution was prepared by adding 15 mmol / L of 3-carboxyphenylboronic acid (3-CPBA), 3-hydroxyphenylboronic acid (3-HPBA) and 3-aminophenylboronic acid (3-APBA), and 100 mmol / L of sorbitol, sucrose, or mannitol, and the test was carried out in the same manner as in Example 1. As a comparative example, a storage solution without adding arylboronic acid was prepared, and the same test was carried out. The results are shown in Table 6. As can be seen from Table 6, even when other arylboronic acids were used, in the case of further adding sorbitol, sucrose, or mannitol, the recovery rate of hemoglobin in the sample was further improved in any of the stool samples of Stool 1, Stool 2, and Stool 3, and it is believed that the stability of hemoglobin in the sample containing stool can be synergistically improved.
[0131] Table 6
[0132]
[0133]
[0134] Example 7
[0135] The phenylboronic acid of the storage solution of Example 1 was set to 0-50mmol / L, and a storage solution of 100mmol / L sorbitol or mannitol was added, and the test was carried out in the same manner as in Example 1. The results are shown in Table 7. As can be seen from Table 7, in the storage solution to which sugar was added, no decrease in the apparent recovery rate was found even when 50mmol / L of phenylboronic acid was added. The reason for this is considered to be that although aryl boronic acid (in high concentration) has the characteristic of inhibiting immune agglutination reaction, the presence of high concentrations of aryl boronic acid will have an adverse effect on the immunological determination method and reduce the apparent recovery rate, but on the other hand, in the case of the coexistence of high concentrations of sugar, the adverse effect of high concentrations of aryl boronic acid on the immunological determination method is suppressed by forming a complex with the sugar.
[0136] Table 7
[0137]
[0138]
[0139] Example 8
[0140] A storage solution was prepared to which 40 mmol / L HEPES (pH 6.8), 0.1% BSA, 0.1% NaN3, and 0-2.5 mmol / L phenylboronic acid were added. In addition, a storage solution to which 0.5 mmol / L of 3-carboxyphenylboronic acid (3-CPBA), 3-hydroxyphenylboronic acid (3-HPBA), and 3-aminophenylboronic acid (3-APBA) were added was combined instead of phenylboronic acid to prepare a storage solution. A stool sample to which hemoglobin was added was added to the storage solution to prepare a sample having a stool concentration of 0.5%, and the sample was stored at 37°C for 0, 16, 38, and 62 hours. In addition, hemoglobin was added to the stool sample in an amount such that the hemoglobin concentration in the sample was about 300 μg / L. Instead of the stool sample to which hemoglobin was added, hemoglobin was added to the storage solution, and a sample not containing a stool sample was stored in the same manner so that the hemoglobin concentration in the sample was 300 μg / L. Using the same measuring reagent and measuring apparatus as in Example 1, the hemoglobin (Hb) concentration (μg / L) in the stored sample was measured by latex agglutination method.
[0141] In this example, since the storage solution does not contain haptoglobin, hemoglobin decomposes faster than in Example 1-7, but the stabilizing effect of arylboronic acid on hemoglobin is also observed in this example. That is, as can be seen from Table 8, in any sample of stool 1, stool 2, and stool 3, the recovery rate of hemoglobin in the sample is improved by adding arylboronic acid at a concentration of 0.25 mmol / L or more. In addition, unlike Example 1-7, since the storage solution does not contain haptoglobin, it is observed that most of the hemoglobin in the sample exists without forming a complex with haptoglobin. Therefore, the above results mean that arylboronic acid also stabilizes hemoglobin that has not formed a complex with haptoglobin.
[0142] Table 8
[0143]
[0144]
[0145] Example 9
[0146] The concentration of phenylboronic acid in the storage solution of Example 8 was fixed at 0.5 mmol / L, and a storage solution was prepared to which 10-250 mmol / L of sorbitol or sucrose, or 50-100 mmol / L of trehalose, glucose, fructose or mannitol was further added, and the test was carried out in the same manner as in Example 8. In addition, a storage solution was prepared to which phenylboronic acid was added but no sugar was added, and as a comparative example, a storage solution was prepared to which phenylboronic acid and sugar were not added, and the same test was carried out. The results are shown in Tables 9A and 9B. As can be seen from Tables 9A and 9B, even in a storage solution not containing haptoglobin, when sorbitol, sucrose, trehalose, glucose, fructose or mannitol was further added to phenylboronic acid, the recovery rate of hemoglobin in the sample was further improved in any of the stool samples of stool 1, stool 2 and stool 3. In addition, even if sugar was added to the storage solution not containing phenylboronic acid, the recovery rate of hemoglobin in the sample containing the stool sample did not increase. These results show that the synergistic effect of phenylboronic acid and various sugars can be obtained in the same manner as in Example 2-7 even in a storage solution not containing haptoglobin.
[0147] Table 9A
[0148]
[0149]
[0150] Table 9B
[0151]
[0152]
[0153] The concentration of phenylboronic acid in the storage solution of Example 8 was fixed at 0.5 mmol / L. In addition, instead of phenylboronic acid, 0.5 mmol / L of 3-carboxyphenylboronic acid (3-CPBA), 3-hydroxyphenylboronic acid (3-HPBA) and 3-aminophenylboronic acid (3-APBA) were added, and 100 mmol / L of sorbitol or sucrose was added to prepare a storage solution, and the test was carried out in the same manner as in Example 8. As a comparative example, a storage solution without adding arylboronic acid was prepared, and the same test was carried out. The results are shown in Table 10. As can be seen from Table 10, even in a storage solution without haptoglobin, the recovery rate of hemoglobin in the sample is further improved by the combination of various arylboronic acids and sugars, and it was observed that the stability of hemoglobin in a sample containing feces can be synergistically improved.
[0154] Table 10
[0155]
[0156]
Claims
1. A method for stabilizing in solution a protein contained in a sample derived from a living body, It is characterized in that The method comprises the steps of allowing the protein contained in the sample derived from the living body to coexist with an arylboronic acid and at least one selected from the group consisting of sugar alcohols, monosaccharides and disaccharides in the solution, The protein contained in the living body-derived sample is at least one selected from the group consisting of hemoglobin and a hemoglobin-haptoglobin complex.
2. The method according to claim 1, in, The aryl boronic acid is at least one selected from the group consisting of phenylboronic acid and derivatives thereof.
3. The method according to claim 1, in, The aryl boronic acid is at least one selected from the group consisting of phenylboronic acid, hydroxyphenylboronic acid, carboxyphenylboronic acid, aminophenylboronic acid, and salts of these boronic acids.
4. The method according to claim 1, in, The step of allowing the protein contained in the sample derived from a living organism to coexist with the arylboronic acid is a step of dispersing the protein contained in the sample derived from a living organism in a solution containing the arylboronic acid. The concentration of the arylboronic acid in the solution is greater than 0.1 mmol / L.
5. The method according to claim 1, in, The at least one selected from the group consisting of sugar alcohols, monosaccharides and disaccharides is at least one selected from the group consisting of sorbitol, glucose, mannitol, fructose, xylitol, erythritol, sucrose, trehalose, lactose, and maltose.
6. The method according to claim 1, in, The step of making the protein contained in the sample derived from the living body coexist with the aryl boronic acid and at least one selected from the group consisting of sugar alcohols, monosaccharides and disaccharides is to disperse the protein contained in the sample derived from the living body in a solution containing the aryl boronic acid and at least one selected from the group consisting of sugar alcohols, monosaccharides and disaccharides, The concentration of the sugar in the solution is above 5 mmol / L.
7. The method according to claim 1, in, The sample derived from a living body at least includes hemoglobin, The method comprises the step of contacting the hemoglobin with haptoglobin to form a complex of the hemoglobin and the haptoglobin.
8. The method according to claim 1, in, The sample derived from a living body is feces, saliva or urine.
9. A stabilizing solution for stabilizing proteins contained in a sample derived from a living body, It is characterized in that contains an arylboronic acid and at least one selected from the group consisting of sugar alcohols, monosaccharides and disaccharides, The protein contained in the living body-derived sample is at least one selected from the group consisting of hemoglobin and a hemoglobin-haptoglobin complex.
10. The stable solution according to claim 9, in, The aryl boronic acid is at least one selected from the group consisting of phenylboronic acid and derivatives thereof.
11. The stable solution according to claim 9, in, The aryl boronic acid is at least one selected from the group consisting of phenylboronic acid, hydroxyphenylboronic acid, carboxyphenylboronic acid, aminophenylboronic acid, and salts of these boronic acids.
12. The stable solution according to claim 9, in, The at least one selected from the group consisting of sugar alcohols, monosaccharides and disaccharides is at least one selected from the group consisting of sorbitol, glucose, mannitol, fructose, xylitol, erythritol, sucrose, trehalose, lactose, and maltose.
13. The stable solution according to claim 9, in, Contains haptoglobin.
14. The stable solution according to claim 9, in, The sample is stool, saliva or urine.
15. The stable solution according to claim 9, in, The stabilizing solution is a solution for preserving the sample derived from a living body.
16. A method for detecting a protein in a sample derived from a living body , It is characterized in that The method comprises: adding the sample derived from a living body to the stable solution according to any one of claims 9 to 15 to obtain a test sample containing the sample; and The step of detecting the protein in the sample by an immunological assay method, The protein in the living body-derived sample is at least one selected from the group consisting of hemoglobin and a hemoglobin-haptoglobin complex.
17. The method according to claim 16, in, The sample derived from a living body at least includes hemoglobin, The hemoglobin in the sample forms a complex with haptoglobin.
18. The method according to claim 17, in, The stabilizing solution contains haptoglobin.
19. A kit for detecting a protein contained in a sample derived from a living body, It is characterized in that include: The stable solution according to any one of claims 9 to 15, and a reagent containing an antibody that recognizes the protein, The protein is at least one selected from the group consisting of hemoglobin and a hemoglobin-haptoglobin complex.
